10.14
Monte Rosa Therapeutics Inc stock is traded at $10.14, with a volume of 1.15M.
It is up +1.20% in the last 24 hours and up +111.23% over the past month.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
See More
Previous Close:
$10.04
Open:
$10
24h Volume:
1.15M
Relative Volume:
1.00
Market Cap:
$626.24M
Revenue:
-
Net Income/Loss:
$-130.41M
P/E Ratio:
-4.5258
EPS:
-2.24
Net Cash Flow:
$-67.76M
1W Performance:
+32.64%
1M Performance:
+111.23%
6M Performance:
+140.76%
1Y Performance:
+106.09%
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
Name
Monte Rosa Therapeutics Inc
Sector
Industry
Phone
617-949-2643
Address
321 HARRISON AVENUE, BOSTON
Compare GLUE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
GLUE
Monte Rosa Therapeutics Inc
|
10.14 | 620.06M | 0 | -130.41M | -67.76M | -2.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.56 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
469.33 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
560.46 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
800.99 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Feb-15-24 | Initiated | Wedbush | Outperform |
Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-13-22 | Initiated | UBS | Buy |
Aug-15-22 | Initiated | Jefferies | Buy |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
View All
Monte Rosa Therapeutics Inc Stock (GLUE) Latest News
Using data models to predict Monte Rosa Therapeutics Inc. stock movementEarnings Beat & High Accuracy Buy Signal Tips - newser.com
Applying sector rotation models to Monte Rosa Therapeutics Inc.Profit Target & Step-by-Step Trade Execution Guides - newser.com
Using economic indicators to assess Monte Rosa Therapeutics Inc. potentialTreasury Yields & AI Powered Market Entry Strategies - newser.com
Why Monte Rosa Therapeutics Inc. stock could benefit from AI revolutionMarket Activity Summary & Technical Pattern Based Buy Signals - newser.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 7.9%Here's Why - MarketBeat
Monte Rosa Therapeutics Inc. stock momentum explainedWeekly Gains Summary & Verified Entry Point Signals - newser.com
What analysts say about Monte Rosa Therapeutics Inc stockValue Traps to Avoid & Outstanding Growth Strategies - earlytimes.in
Does Monte Rosa Therapeutics Inc. fit your quant trading modelJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Monte Rosa Therapeutics Forms Golden Cross, Signals Bullish Breakout Ahead - Markets Mojo
Signal strength of Monte Rosa Therapeutics Inc. stock in tech scannersDollar Strength & Low Drawdown Momentum Trade Ideas - newser.com
Monte Rosa Therapeutics (NASDAQ:GLUE) Earns "Sell (D)" Rating from Weiss Ratings - MarketBeat
Will Monte Rosa Therapeutics Inc. see short term momentum2025 AllTime Highs & Low Drawdown Investment Ideas - newser.com
Comparing Monte Rosa Therapeutics Inc. in custom built stock radarsJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
How high can Monte Rosa Therapeutics Inc. stock goShort Setup & Advanced Technical Analysis Signals - newser.com
Pallas Capital Backs Monte Rosa Therapeutics, Inc. (GLUE) Amid Growth Prospects - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
Is Monte Rosa Therapeutics Inc a good long term investmentGeopolitical Risk Analysis & Consistent Double Returns - earlytimes.in
Monte Rosa Therapeutics Inc Stock Analysis and ForecastLarge Cap Stability Picks & Fast Profit Trading Ideas - earlytimes.in
Full technical analysis of Monte Rosa Therapeutics Inc. stockBuy Signal & Accurate Buy Signal Notifications - newser.com
Is Monte Rosa Therapeutics Inc. stock reversal real or fakeWatch List & Daily Chart Pattern Signals - newser.com
Monte Rosa Therapeutics Inc. stock trend forecastJuly 2025 Fed Impact & Fast Entry High Yield Stock Tips - newser.com
Pallas Capital Advisors LLC Makes New $59,000 Investment in Monte Rosa Therapeutics, Inc. $GLUE - Defense World
Monte Rosa Therapeutics presents new CDK2 degradation inducers - BioWorld MedTech
Monte Rosa Is Building The ‘Next RNAi’ Through AI-Powered Molecular Glue Discovery - insights.citeline.com
Will Monte Rosa Therapeutics Inc. stock go up soonJuly 2025 Fed Impact & Community Consensus Picks - newser.com
Sentiment analysis tools applied to Monte Rosa Therapeutics Inc.July 2025 Big Picture & Stepwise Entry and Exit Trade Signals - newser.com
Q3 EPS Forecast for Monte Rosa Therapeutics Cut by Analyst - MarketBeat
Aug EndMonth: Can Monte Rosa Therapeutics Inc disrupt its industryPortfolio Value Summary & Free High Accuracy Swing Entry Alerts - خودرو بانک
Market Moves: Can Monte Rosa Therapeutics Inc. disrupt its industry2025 Retail Activity & Growth Oriented Trading Recommendations - خودرو بانک
Monte Rosa Therapeutics Inc Stock (GLUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monte Rosa Therapeutics Inc Stock (GLUE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Leo Chandra P. | Director |
Mar 24 '25 |
Buy |
5.84 |
10,000 |
58,383 |
10,000 |
Versant Venture Capital VI, L. | 10% Owner |
Oct 28 '24 |
Sale |
9.66 |
89,990 |
869,240 |
2,007,948 |
Versant Venture Capital VI, L. | 10% Owner |
Oct 29 '24 |
Sale |
9.16 |
67,905 |
621,801 |
1,573,453 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):